<--- Back to Details
First PageDocument Content
AstraZeneca / Chemistry / Alkenes / Prodrugs / Tamoxifen / Treatment of bipolar disorder / Pharmacogenetics / CYP2D6 / Aromatase inhibitor / Pharmacology / Medicine / Selective estrogen receptor modulators
Date: 2006-09-28 09:40:14
AstraZeneca
Chemistry
Alkenes
Prodrugs
Tamoxifen
Treatment of bipolar disorder
Pharmacogenetics
CYP2D6
Aromatase inhibitor
Pharmacology
Medicine
Selective estrogen receptor modulators

Bibliography of publications included in the backgrounder

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 13,56 KB

Share Document on Facebook

Similar Documents

Brad  Hammoor     Biochem  158   Professor  Brutlag   The Future of FDA Regulation of Pharmacogenetics

DocID: 1vlX3 - View Document

Sydney Beache Human Biology 158G The Economic, Ethical, and Social Implications of the Pharmacogenomics Movement I. Introduction to Pharmacogenomics While the term “pharmacogenetics” has been in existence for roughly

DocID: 1u9i0 - View Document

Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing Matthew Fredrikson∗ , Eric Lantz∗ , Somesh Jha∗ , Simon Lin† , David Page∗ , Thomas Ristenpart∗ University of Wisconsin∗

DocID: 1tI4M - View Document

PharmacoGenetics-Pharmarmaconomics.ru № 2, 2017 Ôàðìàêîãåíåòèêà è Ôàðìàêîãåíîìèêà

DocID: 1tDea - View Document

Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing Matthew Fredrikson, Eric Lantz, and Somesh Jha, University of Wisconsin—Madison; Simon Lin, Marshfield Clinic Research Foundation; D

DocID: 1sqsf - View Document